Exchange: NASDAQ·

RVNCRevance Therapeutics Inc

$0.00
$0.00
(0.00%)
Today
Reported EarningsNov 7
Mkt Cap$381.02M
Vol4.12M
News
all
press releases
News Placeholder
Revance Therapeutics Stock’s Retail Sentiment Muted Even As Teoxane Makes Better Offer Than Crown Labs
The offer represents a 16% premium over the $3.10-per-share agreement with Crown Laboratories announced last month.
Stocktwits
News Placeholder
Revance Therapeutics Stock Plummets To 4-Month Low As Crown Labs Halves Takeover Offer: Retail Fumes
The price cut follows a notice received by Revance in September alleging violations of an exclusive distribution agreement with Teoxane.
Stocktwits
<
...
1
>

Advertisement|Remove ads.